Clearing the way for transparency in drug regulation
This article was originally published in Scrip
Executive Summary
Transparency is everything – or so it would appear. Barely a week goes by without new proposals to put more information into the public domain, set new conditions for experts sitting on advisory committees, or limit companies' freedom to hand out gifts.